🔍 Intelligence Synthesis JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-21

A brass-wire and bead network model beside an amber vial and an empty paper ring, suggesting AI findings still awaiting replication.
What this means, as an image (AI-generated, GPT Image): Clinicians should check for external validation before treating AI-derived subtypes or blood markers as ready for care.Download image (PNG, 2000×800)
3 papers in this issue. Lead: DEGAS, disease endophenotyping through graph and adjacency metrics: network biomarkers for Parkinson’s disease progression

New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.

Read by disease: Basic research(0) · ALS(0) · Parkinson's(2) · Hereditary neurodegeneration(0) · Neuromuscular(0) · Multiple sclerosis(1) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)

Neurodegeneration and neuroimmunology research and AI

No new qualifying paper for this issue.

ALS: treatment, trials and AI

No new qualifying paper for this issue.

Parkinson's disease and parkinsonism: treatment, trials and AI

See all 2 Parkinson's papers →

Hereditary neurodegenerative diseases: treatment, trials and AI

No new qualifying paper for this issue.

Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI

No new qualifying paper for this issue.

Multiple sclerosis: treatment, trials and AI

See all 1 Multiple sclerosis papers →

NMOSD and MOGAD: treatment, trials and AI

No new qualifying paper for this issue.

Myasthenia gravis: treatment, trials and AI

No new qualifying paper for this issue.

Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI

No new qualifying paper for this issue.

How papers are chosen: (1) collected from journal feeds, PubMed (all journals) and OpenAlex; (2) editorials, corrections and items without field/AI terms are removed; (3) Jev judges four points (original research ≥ 0.6, AI ≥ 0.6, one of 9 disease groups, treatment/trials ≥ 0.5 for disease groups); (4) ranked by Jev importance up to a daily limit (two per group); (5) the IF-equivalent is shown only when Jev confirms the journal match. Papers Jev cannot judge are not listed.